
Featured
Verve Therapeutics’ CRISPR Gene Editing Permanently Cures Hypertension in Phase 2 Trials
Verve Therapeutics has announced groundbreaking Phase 2 trial results showing that a single CRISPR base-editing infusion can permanently lower high bl...
Read Full Story →